Pharma stocks rallied after reports suggested that the Trump administration may not impose tariffs on generic medicines.
India’s drug regulator, CDSCO, found serious failures in mandatory batch testing at drug facilities and issued an advisory to state…
Imported drugs could become more expensive for patients and healthcare providers if 100% tariffs get a go ahead.
Nomura warns Sun Pharma faces $100 million risk from potential US tariffs on specialty drugs. Explore the impact on Indian…
Dividend stocks this week, September 28: Glenmark Pharma trades ex-dividend on Oct 3; watch for interim Rs 2.5 payout. Check…
Indian pharma stocks fell up to 7% in reaction to the US imposing a 100% tariff on imported branded and…
Donald Trump imposed new tariffs on imported pharmaceutical products. Check out his announcement.
Discover why Nomura predicts a 25% downside for Glenmark Pharma despite its new cancer drug deal—read their analysis before investing!
The US Treasury has sanctioned Indian nationals for supplying counterfeit fentanyl-laced pills that fueled America’s opioid crisis.
India’s GST reform has reduced tax on essential medicines from 12% to 5% and fully exempted 36 life-saving drugs. The…
India’s exports rose 6.7% to $35.1 bn in August 2025, while imports fell 10.1% to $61.6 bn, narrowing the trade…
Zydus Lifesciences has launched VaxiFlu, India’s first trivalent influenza vaccine for seasonal flu protection. The vaccine follows WHO’s 2025–26 guidelines…
Nuvama on Divi’s Laboratories: Nuvama projects a 15% upside for Divi’s Laboratories; discover the three reasons behind this pharma stock’s…
Jefferies names Sai Life, Divi’s, and Cohance as top Indian CRDMO picks with up to 37% upside—see which pharma stocks…
Investors are increasingly turning to ‘safer’ MNC pharma stocks with a domestic focus at a time when the Trump administration…
Sun Pharma slides 6% after weak Q1 FY26 results, but Motilal Oswal still recommends Buy—discover the three reasons to consider…
Jubilant Pharmova reported a 78.66 per cent decline in Q1 profit due to a high base effect, even as revenue…
Despite US tariff concerns, India’s pharmaceutical exports are projected to double to $65 billion by 2030. This growth is fueled…